US 11,052,090 B2
Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection
Raymond F. Schinazi, Miami, FL (US); and Christina Gavegnano, Decatur, GA (US)
Assigned to Emory University, Atlanta, GA (US); and Children's Healthcare of Atlanta, Inc., Atlanta, GA (US)
Filed by Emory University, Atlanta, GA (US); and CHILDREN'S HEALTHCARE OF ATLANTA, INC., Atlanta, GA (US)
Filed on Feb. 12, 2020, as Appl. No. 16/788,374.
Application 16/788,374 is a continuation of application No. 15/741,665, granted, now 10,765,679, previously published as PCT/US2016/040694, filed on Jul. 1, 2016.
Claims priority of provisional application 62/188,624, filed on Jul. 4, 2015.
Prior Publication US 2020/0316073 A1, Oct. 8, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/00 (2006.01); C07K 14/00 (2006.01); C07K 16/28 (2006.01); C07K 14/76 (2006.01); C07K 14/765 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61K 38/08 (2019.01); A61K 38/17 (2006.01); A61K 38/10 (2006.01); A61P 31/14 (2006.01); A61P 31/18 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 38/08 (2013.01); A61K 38/10 (2013.01); A61K 38/17 (2013.01); A61K 38/1709 (2013.01); A61K 45/06 (2013.01); A61P 31/14 (2018.01); A61P 31/18 (2018.01); C12N 2740/16034 (2013.01); Y02A 50/30 (2018.01)] 15 Claims
 
1. A method for treating an AIDS-related neurological disorder, comprising administering to a patient in need thereof an effective antiviral amount of a TREM-1 inhibitor in combination with HAART.